The Status of Exon Skipping as a Therapeutic Approach to Duchenne Muscular Dystrophy
Open Access
- 1 January 2011
- journal article
- review article
- Published by Elsevier BV in Molecular Therapy
- Vol. 19 (1), 9-15
- https://doi.org/10.1038/mt.2010.219
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Functional Rescue of Dystrophin-deficient mdx Mice by a Chimeric Peptide-PMOMolecular Therapy, 2010
- In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophyThe Journal of Gene Medicine, 2010
- Prevention of Dystrophic Pathology in Severely Affected Dystrophin/Utrophin-deficient Mice by Morpholino-oligomer-mediated Exon-skippingMolecular Therapy, 2010
- Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept studyThe Lancet Neurology, 2009
- Rational Design of Antisense Oligomers to Induce Dystrophin Exon SkippingMolecular Therapy, 2009
- A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic deliveryGene Therapy, 2009
- Octa-guanidine Morpholino Restores Dystrophin Expression in Cardiac and Skeletal Muscles and Ameliorates Pathology in Dystrophic mdx MiceMolecular Therapy, 2009
- Sustained Dystrophin Expression Induced by Peptide-conjugated Morpholino Oligomers in the Muscles of mdx MiceMolecular Therapy, 2008
- Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathologyNature Medicine, 2006
- Effective targeted gene ‘knockdown’ in zebrafishNature Genetics, 2000